



(51) International Patent Classification:

C07D 403/04 (2006.01) **C07D 409/10** (2006.01)
C07D 409/04 (2006.01) **C07D 413/10** (2006.01)
C07D 241/38 (2006.01) **C07D 417/04** (2006.01)
C07D 243/10 (2006.01) **C07D 417/10** (2006.01)
C07D 401/04 (2006.01) **C07D 471/04** (2006.01)
C07D 403/10 (2006.01) **C07D 491/04** (2006.01)
C07D 405/04 (2006.01) **C07D 495/04** (2006.01)
C07D 405/10 (2006.01)

(21) International Application Number:

PCT/JP2011/071174

(22) International Filing Date:

12 September 2011 (12.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2010-204747 13 September 2010 (13.09.2010) JP

(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ITO, Nobuaki** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD.,

1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **SASAKI, Hirofumi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **TAI, Kuninori** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP). **SHINOHARA, Tomoichi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).


(74) Agents: **ASAMURA, Kiyoshi** et al.; Tennoz Central Tower, 2-2-24 Higashi-Shinagawa, Shinagawa-ku, Tokyo, 1408776 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE.



(57) Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents -O- or -CH₂-; R¹ represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R² and R³, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R² and R³ are bonded to form a cyclo-C3-C8 alkyl group; and R⁴ represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).



GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))